

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	0	("immunomodulatedexendin").PN.	US-PGPUB; USPAT	OR	OFF	2005/10/18 15:41
L3	0	("immunomodulatedexendin").PN.	US-PGPUB; USPAT	OR	OFF	2005/10/18 15:41
L4	1	immunomodulated exendin	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:41
L5	64910	"1" with immuno\$	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:42
L6	355	exendin-4	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:42
L7	18	6 with immuno\$	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:42
S1	355	exendin-4	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:13
S2	3014	thiazolidinedione	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:06
S3	3	S1 same S2 same diabetes	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:10
S4	249	diabetes related disease	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:10
S5	1	S1 same S2 same S4	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:54
S6	3302	troglitazone or cigitazone or pioglitazone or rosiglitazone or isaglitazone or darglitazone or englitazone	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:54
S7	54	S1 same S6	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:54
S8	23	S7 same diabetes	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:55
S9	23	S8 not S3	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:55
S10	1	("20030087820").PN.	US-PGPUB; USPAT	OR	OFF	2005/10/18 15:40

\$8^STN;HighlightOn= ***;HighlightOff=*** ;
Connecting via Winsock to STN

Connecting via Windsock to STN

Welcome to STN International! Enter x:x
LOGINID: sssptal653raw`

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS VB.0, CURRENT MACINTOSH VERSION IS V6.0C (ENG) AND V6.0JC (JP) AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability General Internet Information WalCome Banner and News Items Direct Dial and Telecommunication Network Access to STN STN World Wide Web Site (general information)
NEWS INTERNET	
NEWS LOGIN	
NEWS PHONE	
NEWS WWW	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer Agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:45:37 ON 18 OCT 2005

=> index biosci
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF

```
=> index bioacci -usdatfull -usdat2  
FILE 'DRUGMONG' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY  
TOTAL SESSION 0.80  
FULL ESTIMATED COST
```

INDEX 'ADISCTI, ADISNSIGHT, AGRICOLA, ANABSTR, ANTE, AQULINE,
AQUASCI, BIOPARTNERS, BIOCENTER, BIOCOMMERCE, BIONG, BIOSIS, BIOTECHB,
BIOTECHNO, CABA, CANCERLUS, CAPLUS, CEBBA-VTB, CEN, CIN, CONSPCI, CROPB,
CROPB, DDFB, DDFI, DGENE, DISSABS, ...' ENTERED AT 15:46:13 ON 18 OCT

2003

72 FILES IN THE FILE LIST IN \$TNINDEX

search error messages that display as 0, with SET DETAIL OFF.

=> s exendin (p) thiazolidinedione
1 FILE ADISINSIGHT

0: FILE ADISNEWS
0: FILE ADISNEWS

O+ FILE AQUALINE

FILE BIOENG

FILE BIOIECHADS FILE BIOTECHADS FILE

FILE BIOTECHNOLOGY

O* FILE CEABA-VTB

196 FILE DGENE

31 FILES SEARCHED
1 FILE DRUG

O: FILE ESBIOBASE

FILE FORMAD

FILE FROST I
FILE FROST II
C+ C+

0' FILE FSTA

0* FILE KOSMET
 0* FILE NTIS
 0* FILE NUTRACEUT
 0* FILE PASCAL
 0* FILE PHARMAL
 1 FILE TOCENTER
 0* FILE WATER
 4 FILE WPIDS
 4 FILE WPINDEX

11 FILES HAVE ONE OR MORE ANSWERS, 72 FILES SEARCHED IN STNINDEX

L1 QUE EXENDIN (P) THIAZOLIDINEDIONE

=> s 11 (p) diabetes

- 1 FILE ADISINSIGHT
- 0* FILE ADISNEWS
- 0* FILE ANTE
- 0* FILE AQUALINE
- 0* FILE BIOMERCE
- 0* FILE BIOENG
- 1* FILE BIOTECHABS
- 1* FILE BIOTECHDS
- 1* FILE BIOTECHNO
- 2 FILE CARPLUS
- 0* FILE CEABA-VTB
- 0* FILE CIN
- 196 FILE DGENE
- 1 FILE DRUGU
- 0* FILE ESBIOBASE
- 0* FILE FEDRIP
- 0* FILE FORAD
- 0* FILE FOREGE
- 0* FILE FROSTI
- 0* FILE FSTA
- 4 FILE IFIPAT
- 0* FILE KOSMET
- 0* FILE NTIS

51 FILES SEARCHED...

- 0* FILE NUTRACEUT
- 0* FILE PASCAL
- 0* FILE PHARMAL
- 0* FILE WATER
- 4 FILE WPIDS
- 4 FILE WPINDEX

10 FILES HAVE ONE OR MORE ANSWERS, 72 FILES SEARCHED IN STNINDEX

L2 QUE L1 (P) DIABETES

=> file hits

COST IN U.S. DOLLARS

FULL ESTIMATED COST

FILE 'DGENE' ENTERED AT 15:49:53 ON 18 OCT 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'IFIPAT' ENTERED AT 15:49:53 ON 18 OCT 2005
 COPYRIGHT (C) 2005 IFIPAT CLAIMS (R) Patent Services (IFI)
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP/USAGE TERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ADISINSIGHT' ENTERED AT 15:49:53 ON 18 OCT 2005
 COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'DRUGU' ENTERED AT 15:49:53 ON 18 OCT 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:49:53 ON 18 OCT 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 15:49:53 ON 18 OCT 2005
 COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s 12

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'EXENDIN (P) THIAZOLIDINEDIONE'

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'LI (P) DIABETES'

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'EXENDIN (P) THIAZOLIDINEDIONE'

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'LI (P) DIABETES'

FIELD CODE - 'AND' OPERATOR ASSUMED 'EXENDIN (P) THIAZOLIDINEDIONE'

FIELD CODE - 'AND' OPERATOR ASSUMED 'LI (P) DIABETES'

L3 210 L2

=> dup rem 13

DUPPLICATE IS NOT AVAILABLE IN 'DGENE, ADISINSIGHT'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE.

PROCESSING COMPLETED FOR L3
L4 208 DUP REM L3 (2 DUPLICATES REMOVED)

=> s 14 and synerg2

L5 4 L4 AND SYNERG2

=> d 15 bib ab 1-4

L5 ANSWER 1 OF 4 IFIPAT COPYRIGHT 2005 IFIPAT/IFIUDB/FICDB
AN 10673585 IFIPAT/IFIUDB/FICDB
T1 COMBINATION TREATMENT USING EXENDINS AND THIAZOLIDINEDIONES
INF Knudsen, Lotte Bjerre, Kalundborg, DK
IN Knudsen, Lotte Bjerre (DK)
PAF Unsigned Or Assigned To Individual (68000)
PA

SINCE FILE ENTRY	TOTAL SESSION
3.54	4.34

PPA Novo Nordisk A/S DK (Probable)
AG NOVO NORDISK PHARMACEUTICALS, INC., 100 COLLEGE ROAD WEST, PRINCETON, NJ,
US 08540, US

PI US 2004180824 A1 20040916
AI US 2003-726734 20031203
PRAI DK 2002-1864 20021203
US 2002-431999P 20021209 (Provisional)

FI US 2004180824 20040916
DT UTILITY; Patent Application - First Publication
FS CHEMICAL

APPLICATION This application claims priority under 35 U.S.C. 119 of Danish application no. PA 2002 01864 filed Dec. 3, 2002 and U.S. Application No. 60/431999 filed Dec. 9, 2002, the contents of which are fully incorporated herein by reference.

CLMN 71

OF 4 IFIPAT COPYRIGHT 2005 IFI on STN
AB The present invention relates to methods for treatment and/or prevention of ***diabetes*** and ***diabetes*** related diseases. More specifically, the methods and uses of the invention pertains to administration of an ***exendin*** compound in combination with administration of a ***thiazolidinedione*** insulin sensitizer.

L5 ANSWER 2 OF 4 IFIPAT COPYRIGHT 2005 IFI on STN
AN 1004626 IFIPAT; IFIUD; IFCDS
T1 EXENDIN DERIVATIVES; HAVING ONE LIPOPHILIC SUBSTITUENT WHICH IS ATTACHED TO THE C-TERMINAL AMINO ACID; TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS

INF Huusfeldt; Per Olaf, Copenhagen K, DK
Knudsen; Liselotte Bjerre, Valby, DK
Madsen; Kjeld, Vaerlose, DK
Nielsen; Per Franklin, Vaerlose, DK
IN Huusfeldt Per Olaf (DK); Knudsen Liselotte Bjerre (DK); Madsen Kjeld (DK); Nielsen Per Franklin (DK)

PAF Unassigned
PPA Novo Nordisk of North America Inc (Probable)
AG Raza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6601, US

P1 US 2001047084 A1 20011129
AI US 1001047084 20010621
RL1 NO 1999-DK66 19990224 CONTINUATION
US 1999-312177 19990514 CONTINUATION
PRAI DK 1998-774 19980227
US 998-84357P 19980505 (Provisional)
FI US 2001047084 20011129
DT UTILITY; Patent Application - First Publication
FS CHEMICAL

CLMN 91 The present invention relates to a derivative of GLP-1 (7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.

AB The present invention relates to a derivative of GLP-1 (7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.

L5 ANSWER 3 OF 4 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2004-480510 [45] WPIDS
DNC 22004-178703

T1 Treating or preventing ***diabetes*** or ***diabetes*** -related disease by administering ***exendin*** -4 compound and ***thiazolidinedione*** insulin sensitizer to patient.

DC A96 B04 D16
IN KNUDSEN, L B
PA (KNUD-1) KNUDSEN L B; (NOVO) NOVO NORDISK AS
CYC 108
PI WO 2004050115 A2 20040617 (200445)* EN 21
RW: AT BE BG BW CH CY DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZUG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM D2 EC EE EG ES FI GB GD GE GM HR ID IL IN IS JP KR KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO PU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW US 2004180824 A1 20040916 (200461)
AU 2003283216 A1 20040623 (200472)
EP 1569682 A2 20030907 (200559) EN
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LV MC MK NL PT RO SE SI SK TR ADT WO 2004050115 A2 WO 2003-DR824 20031201; AU 2004180824 A1 Provisional US 2002-431999P 20021209, US 2003-736734 20031203; AU 2003283216 A1 AU 2003-283216 20031201; EP 1569682 A2 EP 2003-773117 20031201, WO 2003-DR824 20031201
FDT AU 2003283216 A1 Based on WO 2004050115; EP 1569682 A2 Based on WO 2004050115
PRAI US 2002-431999P DK 20021209; DK 2002-1864 20021203 AB WO2004050115 A UPAB: 20040716
NOVELTY - Treating or preventing (M1) ***diabetes*** or ***exendin*** -4 compound and ***thiazolidinedione*** insulin sensitizer to the patient.
DETAILED DESCRIPTION - INDEPNDENT CLAIMS are also included for the following:
(1) use of ***exendin*** -4 compound and ***thiazolidinedione*** insulin sensitizer (1) for the preparation of one or more medicaments for carrying out (M1); and
(2) a pharmaceutical composition (11) comprising ***exendin*** -4 ***thiazolidinedione*** preservative.
ACTIVITY - Antidiabetic; Immunosuppressive; Cytoactive; Anorectic;
Antilipemic; Hypotensive; Antilaraciosclerotic; Cardiovascular-Gen.;
Ophthalmological; Nephrotropic; Neuroprotective.
MECHANISM OF ACTION - Stimulator of beta-cell proliferation. No supporting data is given.
USE - (M1) is useful for treating or preventing ***diabetes*** or type 2 ***diabetes***, related disease chosen from type 1 ***diabetes*** or ***diabetes*** in adults, maturity onset ***diabetes***, polycystic ovarian syndrome, gestational ***diabetes***, obesity, dyslipidemia, hypercholesterolemia, hypertension, arteriosclerosis, atherosclerosis, cardiovascular disease, diabetic retinopathy, background retinopathy, proliferative retinopathy, diabetic nephropathy, neuropathy and diabetic neuropathy, where the patient is human. (M1) is useful for increasing the number of beta-cells in patient. (1) is useful for the preparation of one or more medicaments for carrying out (M1). (11) is useful for carrying out (M1) (all claimed).

Dwg 0/0

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOPBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:46:13 ON 18 OCT 2005
SEA EXENDIN (P) THIAZOLIDINEDIONE

LS ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:166077 CAPLUS
DN 131:194808 CAPLUS

TI GLP-1 derivatives of GLP-1 and exendin with a protracted profile of action
IN Knudsen, Liselotte Bjerre; Hunsfeldt, Per Olaf; Nielsen, Per Franklin;

MAASEN, Kjeld

PA Novo Nordisk A/s, Den.

SO PCT Int. Appl., 70 pp.

DT English

LA English

FAN.CNT 12

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
P1 WO 9943708	A1	19990902	WO 1999-DK86	19990225
W: AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	S2, MW, SD, SL, SZ, UW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	19990225	-----	-----
AU 9932477	A1	19980915	AU 1999-32477	19990225
EP 1056775	A1	20001206	EP 1999-936077	19990225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI	-----	-----	-----	-----
JP 2003522099	T2	20030722	JP 2003-53458	19990225
ZA 9901571	A	19990902	ZA 1999-1571	19990226
US 2001047084	A1	20011129	US 2001-886311	20010621
PRA1 DK 1998-274	A	19980227	-----	-----
US 1998-84357P	P	19980505	-----	-----
WO 1999-DK86	W	19990225	-----	-----
US 1999-312177	B1	19990514	-----	-----
AB The present invention relates to derivs. exendin and of GLP-1(7-C), wherein C is 35 or 36, which derivs. have just one lipophilic substituent which is attached to the C-terminal amino acid residue. The derivs. have a protracted action relative to GLP-1(7-37) and are useful for treating insulin-dependent and noninsulin-dependent diabetes mellitus. The derivs. of the invention can be combined with other antidiabetics or oral hypoglycemic agents. Pharmaceutical formulations contg. the derivs. of the invention are also claimed.	L1	-----	-----	-----
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD	ALL CITATIONS AVAILABLE IN THE RE FORMAT	-----	-----	-----

=> d his

(FILE 'HOME' ENTERED AT 15:45:37 ON 18 OCT 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOPBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:45:58 ON 18 OCT 2005
SEA EXENDIN (P) THIAZOLIDINEDIONE

1 FILE ADISINSIGHT

0* FILE ADISNEWS

0* FILE AQUALINE

0* FILE BIOPCOMMERCE

1* FILE BIOTECHABS

1* FILE BIOTECHDS

1* FILE BIOTECHNO

2 FILE CAPLUS

0* FILE CEABA-VTB

0* FILE CIN

196 FILE DGENE

1 FILE DRUGU

0* FILE ESBIOBASE

0* FILE FDDRIP

0* FILE FOMAD

0* FILE FORGE

0* FILE FROSTI

0* FILE FSTA

4 FILE IFIAT

0* FILE KOSMET

0* FILE NTIS

0* FILE NUTRACEUT

0* FILE PASCAL

0* FILE PHARMNL

1 FILE TOX CENTER

0* FILE WATER

4 FILE WPINDS

4 FILE WPINDEX

0* FILE EXENDIN (P) THIAZOLIDINEDIONE

SEA LI (P) DIABETES

1 FILE ADISINSIGHT

0* FILE ADISNEWS

0* FILE AANTE

0* FILE AQUALINE

0* FILE BIOPCOMMERCE

0* FILE BIOTCH

1* FILE BIOTCHDS

1* FILE BIOTCHNO

2 FILE CAPLUS

0* FILE CEABA-VTB

0* FILE CIN

196 FILE DGENE

1 FILE DRUGU

0* FILE ESBIOBASE

0* FILE FDDRIP

0* FILE FOMAD

O*	FILE FORCE	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
O*	FILE FROST1	EP 1569632 A2 EP 2003-775117 R: 20031201
O*	FILE FSTA	DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
4	FILE IFIPAT	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
O*	FILE KOSMET	US 2004180824 A1 US 2003-726734 20031203
O*	FILE NTIS	PRAI DK 2002-1864 A 20021203
O*	FILE NUTRACEUT	US 2002-431999P P 20021209
O*	FILE PASCAL	WO 2003-DK824 W 20031201
O*	FILE PHARMAML	AB The invention provides methods for treatment and/or prevention of ***diabetes*** And ***diabetes*** -related diseases. More specifically, the methods and uses of the invention pertain to administration of an ***exendin*** -4 compd. in combination with administration of a ***thiazolidinedione*** insulin sensitizer.
4	FILE WATER	INDEX 'ADISCT1, ADISINSIGHT, ADISNEWS, AGRICOLA, ANASTR, ANTE, AQUALINE, AQUASCI, BIOPARTNERS, BIOMERIGE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:45:58 ON 18 OCT 2005
4	FILE WPIDS	INDEX 'ADISCT1, ADISINSIGHT, ADISNEWS, AGRICOLA, ANASTR, ANTE, AQUALINE, AQUASCI, BIOPARTNERS, BIOMERIGE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:46:13 ON 18 OCT 2005
QUE L1 (P) DIABETES	SEA EXENDIN (P) THIAZOLIDINEDIONE	SEA EXENDIN (P) THIAZOLIDINEDIONE

d 18 bib ab	ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN	
2004-490736 CAPLUS	141:47336 Combination treatment for ***diabetes*** and related diseases using exendins and thiazolidinediones	
WO 2004030115	Knudsen, Lotte Bjerre Novo Nordisk A/S, Den	
WO 2004030115	PCT Int. Appl., 31 pp.	
	CODEN: PIXXD2 Patent	
	English	
N.CNT 1	PATENT NO.	KIND DATE APPLICATION NO. DATE
-----	-----	-----
WO 2004030115	A2 20040617	WO 2003-DK824 20031201
WO 2004030115	A3 20040722	-----
W:	AE, AG, AL, AM, AZ, BA, BB, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GB, GH, GM, HR, RU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	-----
RW:	BW, GH, KM, KE, LS, MW, SD, SL, SZ, TE, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TI, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, RU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,	-----

```

0* FILE WATER
4 FILE WPIDS
4 FILE WINDEX
QUE ENDIN (P) THIAZOLIDINEDIONE
-----SEA L1 (P) DIABETES-----
1 FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE ANIE
0* FILE AQUALINE
0* FILE BIOCOMMERCE
0* FILE BIOENG
1 FILE BIOTECHABS
1* FILE BIOTECHDS
1* FILE BIOTECHNO
2 FILE CAPLUS
0* FILE CBA-VTB
0* FILE CIN
196 FILE DGENE
1 FILE DRUGU
0* FILE ESPIOBASE
0* FILE FEDRIP
0* FILE FORAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
4 FILE IFPAT
0* FILE KOSMET
0* FILE NTLS
0* FILE NUTRAEUT
0* FILE PASCAL
0* FILE PHARMML
0* FILE WATER
4 FILE WPIDS
a FILE WINDEX
QUE L1 (P) DIABETES

```

FILE 'DGENE, IFIPAT, WPIDS, CAPLUS, ADISINSIGHT, DRUGU, BIOTECHDS,
BIOTECHNO' ENTERED AT 15:49:53 ON 18 OCT 2005
210 S L2
208 DUP REM 13 (2 DUPLICATES REMOVED)
4 S L4 AND SYNERG?
74 S THIAZOLIDINEDIONE AND DIABETES AND SYNERG?
5 S L6 AND EXENDIN
1 S L7 NOT L5
1 S L8

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS		45.29	49.63
FULL ESTIMATED COST			
CA SUBSCRIBER PRICE		-1.46	-1.46